Table of Contents

Dravet syndrome

This article needs significant updating in light of recent advances in this field(LIST).

~~AUTHORS:off~~

Charlotte Dravet (Born 14 July 1936)

Severe myoclonic epilepsy in infancy (SME) was described by Charlotte Dravet in 1978. In the Revised ILAE classification of epilepsies, the SMEI is named “Dravet syndrome” because of the lack of myoclonic seizures in many patients and is considered under Electroclinical syndromes[1]. Dravet syndrome is characterized by febrile and afebrile generalized and unilateral clonic or tonic clonic seizures that occur in the first year of life in an otherwise normal infant and are later associated with myoclonus, atypical absences, and partial seizures. All seizure types are resistant to antiepileptic drugs with developmental delay becomes apparent within the second year of life and is followed by definite cognitive impairment and personality disorders.

Epidemiology

Clinical features

Neurologic Abnormalities

Seizure semiology

Neurophysiology

Neuroimaging

Genetics

Pathophysiology

Outcome

Long term outcome is unfavourable with persistent seizures and severe cognitive impairments. The mortality rate is very high. It is important to carefully treat the prolonged convulsive seizures during the early years of life.

The stagnant or delayed development during the first 6 years subsequently evolves positively although in a dysharmonic way and patients might be able to receive and benefit from specialized educational input in later years.

Treatment

Extremely resistant to any kind of treatment during the first years The partial seizures, myoclonic seizures, and atypical absences tend to disappear later while the convulsive seizures persist. They preferentially occur during the night and can be repeated during the same night, particularly in the case of fever, and then again preceded by myoclonias. Drug therapy

Phenobarbital (PB), valproate (VPA), Phenytoin and benzodiazepines (clonazepam (CZP), Nitrazepam, Clobazam (CLB)) may decrease the frequency and the duration of convulsive seizures.

VPA, benzodiazepines, ethosuximide, high doses of piracetam, can improve the myoclonic syndrome. Zonisamide (ZNS) when started early has been reported to prevent the appearance of myoclonias

Clorazepate, methsuximide, acetazolamide, allopurinol, and sulthiame have also been used with partial results.

Bromide (Brk) has been found to be beneficial particularly for the treatment of refractory grand-mal epilepsy in SME with excellent short term outcomes. In Japan BrK is often used first in conjunction with VPA or CZP, ZNS, clorazepate, and ketogenic diet is introduced if drug therapy is not sufficient.

Corticosteroids can be useful in cases of repeated status, but do not have any long term benefits. Immunotherapy has also been reported to be of some benefit.

Newer AEDs Lamotrigine (LTG) worsens the condition and is contraindicated

Carbamazepine is also believed to worsen the condition. The use of CBZ has been suggested in the early phase of the epilepsy as a test to confirm the diagnostic of SME when it is suspected.

Vigabatrin also has been found to be beneficial on convulsive and partial seizures in our older patients, when the myoclonic syndrome was attenuated.

Topiramate has been shown to achieve excellent control of the convulsive and partial seizures in children and adults.

Rufinamide, with a pharmacologic mechanism similar to carbamazepine and phenytoin may also exacerbate seizures

Stiripentol -The use of Stiripentol, in association with VPA and CLB was shown to be efficacious on convulsive seizures. Stiripentol is mainly beneficial on the status in the first stage of the disease. This therapy is accepted today as the gold standard for this syndrome.

A ketogenic diet may be helpful in some cases and has recently shown to be beneficial in children receiving a combination of Stiripentol, VPA and CLB[6].

It is very important to aggressively treat the status episodes and prophylaxis of infections and hyperthermia. Rectal diazepam can prevent the evolution into status in the case prolonged or repeated convulsive seizures. IV Benzodiazepines are best for status particularly Clonazepam (CZP), Midazolam along with Chloral hydrate or barbiturates.

In the case of prolonged or repeated convulsive seizures, the use of rectal diazepam can prevent the evolution into status. In case of status, the best drugs are the intravenous benzodiazepines, particularly the CZP and the midazolam associated with chloral hydrate or barbiturates.

Other treatments

The photo and pattern sensitivities associated with self-stimulation are extremely drug resistant and can produce long-lasting obtundation and myoclonic status in patients with Dravet syndrome. Wearing sunglasses is usually not enough.

Since monocular light stimulation fails to provoke epileptic discharges, complete inhibition of the self-stimulation can be obtained by using glasses masking one eye has been tried but tolerance is poor. Optical filters tinted with a particular color (the procion turquoise blue = MGL), have been used in Japan to inhibit flickering hand movements and forced eye closure, but again children tolerate this poorly.

Specially adapted blue-tinted contact lenses that had transmission spectra similar to that of MGL have also been used with some benefit. After a period of adjustments, the flicker hand movements have been shown to disappear completely and the self-stimulation by hand flicker movement did not return even after the contact lenses were removed later. The forced eye closure self-stimulation however has not yet been successfully inhibited.

Epilepsy surgery

Andrade et al (2010)[7] reported two adults aged 19&34 with Dravet syndrome who were treated with thalamic deep brain stimulation (DBS) , where the 19yr old showed marked improvement over a 10yr follow up, while the other did not.Small case series have also reported that palliative epilepsy surgery including Vagal Nerve Stimulation (VNS) and corpus callosotomy (CC) can be effective at reducing seizure frequency in Dravet syndrome[8].

The presumed topography of the epileptogenic areas involves preferentially the mesial frontal lobe, the central area, sometimes the parietal and, even, the occipital lobes. Few interictal foci are localized in the temporal area. Surprisingly a hippocampal sclerosis has not been shown in the MRI of these patients who had prolonged and repeated severe FS[reference needed].

Cannabidiol

Differential Diagnoses

The criteria for this syndrome are generalized and/or unilateral clonic or tonic clonic seizures in normal infants, occurring in the first year; almost no other type of seizures occur throughout the course;

EEG is normal at the initial stage, and then shows rather poor epileptiform discharges, such as generalized spike-waves or polyspike-waves without focal abnormalities.

There is inefficiency of treatment. Psychomotor development is normal in the first stage and then slows down. Thus, the initial stage is very near that of SME. These conditions are thought to be all part of one infantile refractory grand mal syndrome with the same physiopathological basis and poor prognosis.

The SCN1A gene mutation has also been demonstrated in patients with borderline SME and in patients with only refractory grand-mal seizures. However, as already underlined, these findings remain heterogeneous and not easy to explain and they are not sufficient to put all the cases together in the same syndrome.

The early diagnosis of SME thus remains a challenge. To summarise the diagnosis is probable when the first seizure occurs between 2 and 9 months, in a neurologically normal baby, when the first two seizures are clonic, generalized or alternating, when they are afebrile or triggered by a moderately high temperature, and when the development is normal during the first year.

Relationship between DS and GEFS+ Recent advances in the molecular genetic studies, suggest that DS may be due to a channelopathy related to the GEFS+ syndrome, a condition which also exhibitis fever sensitivity.

DS shares the same gene with GEFS+, wich was described by Scheffer and Berkovic in 1997 in a large Australian family with epilepsy. GEFS+ is an autosomal-dominant disorder in which the seizures start early and persist beyond 6 years of age. In the affected family coexist members with FS, FS+ and various types of afebrile seizures, such as GTCS, absence, atonic, myoclonic and also partial seizures. .

The afebrile seizures usually begin in childhood a continuum with febrile seizures being characteristic, occurring often after a variable seizure-free period. The prognosis is relatively benign without severe neurologic impairment. Affected members can exhibit more severe epileptic syndromes such as myoclonic astatic epilepsy (MAE), LG, and rarely DS.

GEFS+ is a heterogeneous genetic syndrome caused by more genes. The first gene is SCN1B located on 19q 13.1 encoding the beta 1 subunit of the neuronal voltage- gated sodium channel. A second gene map in the region 2q21-q33 on SCN1A as in DS and finally a third SCN2A gene is located on 2q21-q23 encoding the alfa 2 subunit of the voltage-gated sodium channel. Some patients have also expressed an abnormality in another gene of the gamma aminobutyric acid receptor (GABA A) on chromosome 5q34

Currently DS, the less severe borderline forms (SMEB) and GEFS+, are considered as a continuum of the same condition

Sodium channel Gene for DS and GEFS+

Gene Epilepsy syndrome
SCN1A GEFS+
SMEI (Dravet syndrome)
SCN2A GEFS+
BFNIS (benign familial neonatal infantile seizures)
SCN2B GEFS+

Catterall et al (2010)[15] proposed the hypothesis that increasing severity of loss of function mutations of NaV1.1 channels causing increasing impairment of action potential firing in GABAergic inhibitory neurons is responsible for the spectrum of severity of the NaV1.1-associated forms of epilepsy

Mild impairment of NaV1.1 channel function causes febrile seizures; moderate to severe impairment of NaV1.1 function by missense mutations and/or altered mRNA processing causes the range of phenotypes observed in GEFS+ epilepsy; and very severe to complete loss of function causes SMEI.

There is a wide variation among the phenotypes in these conditions and is possibly due to the strong influence of the genetic background.

References


1. a Berg AT, Berkovic SF, Brodie MJ, Buchhalter J, Cross JH, van Emde Boas W, Engel J, French J, Glauser TA, Mathern GW, Moshé SL, Nordli D, Plouin P, Scheffer IE. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia. 2010 Apr;51(4):676-85. doi: 10.1111/j.1528-1167.2010.02522.x. Epub 2010 Feb 26.
[PMID: 20196795] [DOI: 10.1111/j.1528-1167.2010.02522.x]
2. a Takahashi Y, Fujiwara T, Yagi K, Seino M. Photosensitive epilepsies and pathophysiologic mechanisms of the photoparoxysmal response. Neurology. 1999 Sep 22;53(5):926-32. doi: 10.1212/wnl.53.5.926.
[PMID: 10496248] [DOI: 10.1212/wnl.53.5.926]
3. a Marini C, Scheffer IE, Nabbout R, Suls A, De Jonghe P, Zara F, Guerrini R. The genetics of Dravet syndrome. Epilepsia. 2011 Apr;52 Suppl 2:24-9. doi: 10.1111/j.1528-1167.2011.02997.x.
[PMID: 21463275] [DOI: 10.1111/j.1528-1167.2011.02997.x]
4. a, b, c Yu FH, Mantegazza M, Westenbroek RE, Robbins CA, Kalume F, Burton KA, Spain WJ, McKnight GS, Scheuer T, Catterall WA. Reduced sodium current in GABAergic interneurons in a mouse model of severe myoclonic epilepsy in infancy. Nat Neurosci. 2006 Sep;9(9):1142-9. doi: 10.1038/nn1754. Epub 2006 Aug 20.
[PMID: 16921370] [DOI: 10.1038/nn1754]
5. a, b Lossin C. A catalog of SCN1A variants. Brain Dev. 2009 Feb;31(2):114-30. doi: 10.1016/j.braindev.2008.07.011. Epub 2008 Sep 19.
[PMID: 18804930] [DOI: 10.1016/j.braindev.2008.07.011]
6. a Nabbout R, Copioli C, Chipaux M, Chemaly N, Desguerre I, Dulac O, Chiron C. Ketogenic diet also benefits Dravet syndrome patients receiving stiripentol: a prospective pilot study. Epilepsia. 2011 Jul;52(7):e54-7. doi: 10.1111/j.1528-1167.2011.03107.x. Epub 2011 May 13.
[PMID: 21569025] [DOI: 10.1111/j.1528-1167.2011.03107.x]
7. a Andrade DM, Hamani C, Lozano AM, Wennberg RA. Dravet syndrome and deep brain stimulation: seizure control after 10 years of treatment. Epilepsia. 2010 Jul;51(7):1314-6. doi: 10.1111/j.1528-1167.2009.02408.x. Epub 2009 Nov 16.
[PMID: 19919661] [DOI: 10.1111/j.1528-1167.2009.02408.x]
8. a Dlouhy BJ, Miller B, Jeong A, Bertrand ME, Limbrick DDJ, Smyth MD. Palliative epilepsy surgery in Dravet syndrome-case series and review of the literature. Childs Nerv Syst. 2016 Sep;32(9):1703-8. doi: 10.1007/s00381-016-3201-4. Epub 2016 Jul 27.
[PMID: 27465677] [DOI: 10.1007/s00381-016-3201-4]
9. a Devinsky O, Cross JH, Wright S. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. N Engl J Med. 2017 Aug 17;377(7):699-700. doi: 10.1056/NEJMc1708349.
10. a Lattanzi S, Brigo F, Trinka E, Zaccara G, Striano P, Del Giovane C, et al. Adjunctive Cannabidiol in Patients with Dravet Syndrome: A Systematic Review and Meta-Analysis of Efficacy and Safety. CNS Drugs. 2020 Mar;34(3):229-241. doi: 10.1007/s40263-020-00708-6.
11. a Miller I, Perry MS, Saneto RP, et al. Cannabidiol (CBD; 10 and 20mg/kg/day) significantly reduces convulsive seizure frequency in children and adolescents with Dravet syndrome (DS): Results of a dose-ranging, multi-center, randomized, double-blind, placebo-controlled trial (GWPCARE2) Presented at: 2019 American Academy of Neurology Annual Meeting. May 4-10, 2019; Philadelphia, PA.
12. a Friedman D, French JA, Maccarrone M. Safety, efficacy, and mechanisms of action of cannabinoids in neurological disorders. Lancet Neurol. 2019 May;18(5):504-512. doi: 10.1016/S1474-4422(19)30032-8. Epub 2019 Mar 22.
13. a Devinsky O, Nabbout R, Miller I, Laux L, Zolnowska M, Wright S, et al. Long-term cannabidiol treatment in patients with Dravet syndrome: An open-label extension trial. Epilepsia. 2019 Feb;60(2):294-302. doi: 10.1111/epi.14628. Epub 2018 Dec 23.
14. a Seino M, Higashi T. The investigation on a group of secondary generalized epilepsy in childhood with onset in infancy and refractory grand mal. In: Kimura M, ed. Mental and physical disability research group sponsored by Ministry of Health and Welfare. Report of research group of children's health and environment. 1978:79–80
15. a Catterall WA, Kalume F, Oakley JC. NaV1.1 channels and epilepsy. J Physiol. 2010 Jun 1;588(Pt 11):1849-59. doi: 10.1113/jphysiol.2010.187484. Epub 2010 Mar 1.